SUPPLEMENTARY FIGURES AND TABLES



Supplementary Figure S1: The expression of total c-Met and phospho-Erk1/2 in glioma cells transduced with c-Met-specific shRNA-expressing Ad. Human glioma cancer cells (U251N and U87MG) were transduced with dl/LacZ, dl/shMet4, dl/ shMet5, or dl/shMet4+5 at 200 MOI. After 72 hr, cell lysates were assessed for total c-Met and phospho-Erk1/2 by western blot analysis. Results are representative of three independent experiments.



Supplementary Figure S2: The c-Met expression and viability of normal cell transduced with c-Met-specific shRNA-expressing Ads. (A) HDF cells were transduced with dl/LacZ, dl/shMet4, dl/shMet5, or dl/shMet4+5 at 200 MOI. After 72 hr, total c-Met and phospho-c-Met expression level was observed by western blot analysis. Results are representative of three independent experiments. (B) Effect of c-Met-specific shRNA-expressing Ad on the viability of human normal cells. HDF normal cells were transduced with dl/LacZ or dl/shMet4+5 at 100 or 200 MOI for 72 hr. Result are expressed as a percentage of control (PBS-treated cells).



Supplementary Figure S3: The expression level of phospho-S6. U343 cells were transduced with dl/LacZ or dl/shMet4+5 at 100 MOI. After 4 hr, cells were analyzed with antibody against phospho-S6. Results are representative of three independent experiments.

Gene	Primer sequence	Product (bp)
SM22		
Forward	5'-TGGCGTGATTCTGAGCAA-3'	534
Reverse	5'-CTGCCAAGCTGCCCAAGG-3'	
TGase II		
Forward	5'-CTCGTGGAGCCAGTTATCAACAGCTAC-3'	310
Reverse	5'-TCTCGAAGTTCACCACCAGCTTGTG-3'	
PAI-1		
Forward	5'-GTGTTTCAGCAGGTGGCGC-3'	300
Reverse	5'-CCGGAACAGCCTGAAGAAGTG-3'	
β-actin		
Forward	5'-CGTCTTCACCATGGAGA-3'	310
Reverse	5'-CGGCCATCACGCCCACAGTTT-3'	

Supplementary Table 1: Primer information for cellular senescence gene

Supplementary Table 2: Development of AVOs in PBS-, dl/lacZ-, or dl/shMet4+5-treated U343 cells. Tumor cells were transduced with dl/lacZ or dl/shMet4+5 at an MOI of 30, 50, and 100 for 72 hr. Red fluorescence in acridine orange-stained cells was detected by FACS analysis.

	PBS	dl/LacZ	dl/shMet4+5
30 MOI	7.22 ± 1.19	11.28 ± 0.71	18.97 ± 1.75
50 MOI	7.22 ± 1.19	11.08 ± 0.1	20.44 ± 0.62
100 MOI	7.22 ± 1.19	14.47 ± 3.26	22.88 ± 2.29